BioNTech SE · NASDAQ:BNTX
BioNTech — Shareholder Meeting (May 2024)
31 slides from BioNTech's shareholder meeting presentation, May 17, 2024
Slide 1: Annual General Meeting (AGM) 17 May 2024
Annual General Meeting (AGM) 17 May 2024 Exhibit 99.2
Slide 2: Management Report
Management Report 2 Financial Development 2023 & Q1 2024 und Financial Outlook 2024 Jens Holstein, Chief Financial Officer 1 Operations Development 2023 & Q1 2024 and Outlook 2024 Prof. Dr. Ugur Sahin, Chief Executive Officer & Co-Founder
Slide 3: Operations Development 2023 & Q1 2024 and Outlook 2024
1 Operations Development 2023 & Q1 2024 and Outlook 2024 Prof. Dr. Ugur Sahin, CEO & Co-Founder
Slide 4: This Slide Presentation Includes Forward-Looking Statements
This Slide Presentation Includes Forward-Looking Statements 4 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profi
Slide 5: Our Vision
Our Vision Using the full potential of the immune system to develop new immunotherapies and vaccines
Slide 6: Our Vision: Harnessing the Power of the Immune System to Fight Human Disease
Our Vision: Harnessing the Power of the Immune System to Fight Human Disease 6 AI = artificial intelligence. Innovative precision medicine pipeline targeting multiple product approvals in oncology in the coming years Multi-product immunotherapy pioneer addressing medical need worldwide Sustainable r
Slide 7: Diversified Oncology Pipeline
Diversified Oncology Pipeline
Slide 8: Root Cause of Cancer Treatment Failure
Intraindividual variability & intratumoral heterogeneity driving evasion and secondary resistance mechanism Root Cause of Cancer Treatment Failure Cancer cells Genetically diverse & adaptable5-20 Years – up to 10,000 mutations Mutations DNA Mutation Healthy Cell Mutations Mutations Mutations Mutatio
Slide 9: Towards a Potentially Curative Approach to Cancer: Differentiated Combinations
Towards a Potentially Curative Approach to Cancer: Differentiated Combinations Space for potentially curative approaches Immunomodulators Novel checkpoint inhibitors, cytokines, immune agonists mRNA vaccines Targeted therapy ADCs, CAR-T, TCR-T, small molecules SynergySynergy Synergy 9 CAR = chimeric
Slide 10: Investing Through Waves of Innovation to Transform Cancer Treatment
Investing Through Waves of Innovation with the Aim to Transform Cancer Treatment 10 mRNA cancer vaccines ADCs Immunomodulators Cell Therapy Mid Term 1st wave of oncology launches planned from 2026 onwards Unlock value with initial combination trials Expanding across indication and treatment lines Lo
Slide 11: Sustainable Pipeline for COVID-19 and Other Infectious Diseases
Sustainable Pipeline for COVID-19 and Other Infectious Diseases
Slide 12: We Made History
We Made History 12 1. Ball P. Nature. 2021; 2. Measured by sales recorded for a single product in a single year (>$40 billion combined of direct sales recorded by Pfizer or BioNTech in both 2021 and 2022); 3. Cumulative doses shipped in the years 2021, 2022 and 2023. 4. COVID-19 Excess Mortality Col
Slide 13: Long-Term Need for Annually Adapted Vaccines Anticipated
Variant-adapted vaccines Designed to be effective against multiple variants of concern5 Long-term health consequences Accumulating evidence demonstrates that COVID-19 vaccination reduces long- COVID4 Continuous evolution Ongoing antigenic evolution of SARS-CoV-21,2 Risk remains high For severe COVID
Slide 14: COVID-19 Franchise: Adaptable Approach in the Face of Dynamic Virus Evolution
COVID-19 Franchise1: Adaptable Approach in the Face of Dynamic Virus Evolution for Continued Success 14 1. Partnered with Pfizer. Launch of seasonal adapted vaccine If approved, earliest potential introduction of combination respiratory vaccines Expect continued shift to single dose vials and pre-fi
Slide 15: Infectious Diseases: Important Clinical Development Area
15 HSV Malaria Tuberculosis Mpox 3.7 billion people under age 50 globally infected with HSV-2 ~491 million people aged 15-49 infected with HSV-1 worldwide ~249 million cases in 2022 608,000 deaths in 2022 in 85 countries 10.6 million cases globally in 2022 1.3 million deaths globally in 2022 95,000
Slide 16: Execution in 2023
— Execution in 4 2023 : = 7 SIONT=CH
Slide 17: Developing an Innovative Pipeline Focused on Oncology and Infectious Disease
O n c o lo g y In fe c ti o u s D is e a s e 8 clinical trials started in 2023 and Q1 2024 Growing clinical stage pipeline 6 clinical assets in-licensed in 2023 3 first-in-human trials started in 2023 10 Phase 2 & 3 trials ongoing Developing an Innovative Pipeline Focused on Oncology and Infectious
Slide 18: Corporate Execution in 2023 and Q1 2024
Corporate Execution in 2023 and Q1 2024 1. Consists of cash and cash equivalents of €8,976.6 million and security investments of €7,962.7 million as of March 31, 2024. AI = artificial intelligence; ADC = antibody drug conjugate; IO = immune oncology; CAR = chimeric antigen receptor 18 Strong cash po
Slide 19: BioNTech Today
BioNTech Today1 1. As of 31 December 2023. United Kingdom London Cambridge Rwanda Kigali BioNTainer Austria Vienna Germany Mainz (HQ) Marburg Idar-Oberstein Neuried Planegg-Martinsried Singapore U.S. Cambridge Gaithersburg China Shanghai Türkiye Istanbul BioNTech locations 19 Australia BioNTainer (p
Slide 20: Accelerate and Enhance BioNTech's AI Vision
Accelerate and Enhance BioNTech’s AI Vision 20 AI = artificial intelligence; ML = machine learning. Leverage the power of computational science & AI Implementation strategy • Optimize design of product candidates • Speed up workflows to develop novel therapeutics & vaccine product candidates • Scale
Slide 21: Healthcare and Social Responsibility
Healthcare and Social Responsibility 21 1. Tuberculosis program run in collaboration with the Bill & Melinda Gates Foundation, Mpox partnered with the Coalition for Epidemic Preparedness Innovations (CEPI), Malaria wholly owned program; 2. Partnered with Pfizer, 3. As of December 2023. Inaugurated m
Slide 22: Outlook 2024
— Outlook ‘ 2024 7 SIONT=CH
Slide 23: Strategic Vision for 2030
Cash position Respiratory vaccine franchise Oncology pipeline Infectious diseases pipeline Strategic Vision for 2030 23 1. Consists of cash and cash equivalents of €8,976.6 million and security investments of €7,962.7 million as of March 31, 2024. €16.9 bn cash1 Market-leading and cashflow generatin
Slide 24: Financial Development 2023 & Q1 2024 and Financial Outlook 2024
2 Financial Development 2023 & Q1 2024 and Financial Outlook 2024 Jens Holstein, CFO
Slide 25: FY 2023 Key Financial Figures
FY 2023 Key Financial Figures1 25 Profit before tax € 3.83 € 1.2 bn€ 3.8 bn € 17.7bn Total revenues Diluted EPS 1. Financial information is prepared and presented in Euros and numbers are rounded to millions and billions of Euros in accordance with standard commercial practice; 2. Consists of cash a
Slide 26: FY 2023 Guidance vs. Actuals
FY 2023 Guidance vs. Actuals1 26 COVID-19- vaccine revenues BioNTech COVID-19 vaccine revenues ~ €4 bn €3.8 bn Expenses and capex R&D expenses2 €1,800 – 2,000 m €1,783 m SG&A expenses3 €600 – 650 m €558 m Capital expenditure for operating activities €200 – 300 m €276 m Tax assumptions BioNTech Group
Slide 27: FY 2023 Capital Transactions
FY 2023 Capital Transactions 27 Repurchased ADSs 1 to be held in treasury Period Number of purchased ADSs Percentage of share capital2 Average price Volume Share Repurchase Program 2022 (second tranche 3 ) Jan. to Mar. 2023 2,221,171 0.9% $136.02 $302.1 m Share Repurchase Program 2023 Jun. to Sep. 2
Slide 28: Q1 2024 Key Financial Figures
Q1 2024 Key Financial Figures1 28 Research & development expenses € (332) m € 508 m€ 188 m € 16.9 bn Total revenues (Loss) before tax Total cash plus security investments2 1. Financial information is prepared and presented in Euros and numbers are rounded to millions and billions of Euros in accorda
Slide 29: 2024 Financial Year Guidance Reiterated
2024 Financial Year Guidance Reiterated1 29 Revenue guidance consideration: Top-line sensitivity mainly dependent on the following factors • Vaccination rates and price levels in markets where significant Comirnaty sales are expected • Inventory write-downs • Anticipated revenues related to service
Slide 30: Save the date: Innovation Series
Save the date Innovation Series: AI Day October 1, 2024 Annual Innovation Series November 14, 2024
Slide 31: Thank you for your attention.
Thank you for your attention.